Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

Authors: Huanan Wang, Lei Wang, Yingjie Zhang, Ji Wang, Yibin Deng, Degui Lin

Published in: Cancer Cell International | Issue 1/2016

Login to get access

Excerpt

Following the publication of the original article [1] it was brought to our attention that there are a number of major errors within the text which were not picked up upon by the authors until after publication. …
Literature
1.
Wang H, Wang L, Zhang Y, Wang J, Deng Y, Lin D, et al. Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int. 2016;16:9.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth
Authors
Huanan Wang
Lei Wang
Yingjie Zhang
Ji Wang
Yibin Deng
Degui Lin
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2016
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-016-0313-6

Other articles of this Issue 1/2016

Cancer Cell International 1/2016 Go to the issue

Review

Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?

Primary research

Autophagy induced by a sulphamoylated estrone analogue contributes to its cytotoxic effect on breast cancer cells

Review

The zebrafish as a model for studying neuroblastoma

Hypothesis

Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells

Primary Research

Cytotoxic and apoptogenic effect of hypericin, the bioactive component of Hypericum perforatum on the MCF-7 human breast cancer cell line

Primary research

Long non-coding RNA DBCCR1-003 regulate the expression of DBCCR1 via DNMT1 in bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits